Pfizer Canada Secures PADCEV Plus KEYTRUDA Approval
KIRKLAND, Quebec, Canada, June 29, 2026 Pfizer Canada ULC announced that Health Canada has approved PADCEV® (enfortumab vedotin) in...
Muscle-Invasive Bladder Cancer
Advertisement
Merck’s KEYTRUDA and Padcev Combination Shows Strong Survival Benefit Ahead of EU Approval
RAHWAY, New Jersey, May 24, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Astellas’ PADCEV Combo Wins CHMP Support in MIBC
Tokyo, Japan – May 22, 2026 Astellas Pharma Inc. announced that the European Medicines Agency’s Committee for Medicinal Products...
Mabwell Showcases Strong 9MW2821 Bladder Cancer Data at ASCO 2026
SHANGHAI, China, 22 May 2026 Mabwell announced that new clinical data for its investigational Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821...
Advertisement
